Aduro BioTech (NASDAQ:ADRO) Posts Earnings Results, Misses Estimates By $0.10 EPS

Aduro BioTech (NASDAQ:ADRO) announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.10), Fidelity Earnings reports. Aduro BioTech had a negative net margin of 784.73% and a negative return on equity of 63.81%. The company had revenue of $3.94 million during the quarter, compared to the consensus estimate of $8.08 million.

Shares of ADRO opened at $3.10 on Friday. The company has a market cap of $248.13 million, a P/E ratio of -2.67 and a beta of 2.05. The company has a debt-to-equity ratio of 0.29, a quick ratio of 9.11 and a current ratio of 9.11. Aduro BioTech has a twelve month low of $2.34 and a twelve month high of $9.00.

In related news, CFO Jennifer Lew sold 18,602 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $4.20, for a total transaction of $78,128.40. Following the transaction, the chief financial officer now owns 139,381 shares of the company’s stock, valued at $585,400.20. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders have sold 45,284 shares of company stock worth $184,335. Insiders own 5.20% of the company’s stock.

An institutional investor recently raised its position in Aduro BioTech stock. Geode Capital Management LLC lifted its stake in Aduro BioTech Inc (NASDAQ:ADRO) by 11.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 627,397 shares of the biotechnology company’s stock after acquiring an additional 63,447 shares during the period. Geode Capital Management LLC owned approximately 0.79% of Aduro BioTech worth $1,656,000 at the end of the most recent reporting period. 41.97% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently weighed in on the stock. BidaskClub lowered shares of Aduro BioTech from a “hold” rating to a “sell” rating in a research report on Friday, March 29th. Svb Leerink restated an “outperform” rating and set a $9.00 price objective on shares of Aduro BioTech in a research report on Monday, April 15th. Cowen reaffirmed a “buy” rating on shares of Aduro BioTech in a research note on Wednesday, May 8th. Zacks Investment Research lowered shares of Aduro BioTech from a “buy” rating to a “hold” rating in a research note on Tuesday, May 7th. Finally, ValuEngine lowered shares of Aduro BioTech from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $7.68.

ILLEGAL ACTIVITY WARNING: “Aduro BioTech (NASDAQ:ADRO) Posts Earnings Results, Misses Estimates By $0.10 EPS” was originally published by Rockland Register and is owned by of Rockland Register. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://rocklandregister.com/2019/05/31/aduro-biotech-adro-releases-earnings-results-misses-expectations-by-0-10-eps.html.

Aduro BioTech Company Profile

Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.

Further Reading: Why do companies issue stock splits?

Earnings History for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.